Health status measured by Kansas City Cardiomyopathy Questionnaire-12 in primary prevention implantable cardioverter defibrillator patients with heart failure

被引:2
|
作者
Mattsson, Gustav [1 ]
Wallhagen, Marita [2 ]
Magnusson, Peter [1 ,3 ]
机构
[1] Uppsala Univ Reg Gavleborg, Ctr Res & Dev, S-80187 Gavle, Sweden
[2] Univ Gavle, Dept Bldg Engn Energy Syst & Sustainabil Sci, S-80176 Gavle, Sweden
[3] Karolinska Inst, Cardiol Res Unit, Dept Med, S-17176 Stockholm, Sweden
关键词
Cardiomyopathy; Heart failure; Implantable cardioverter defibrillator; Kansas City Cardiomyopathy Questionnaire; Quality of life; QUALITY-OF-LIFE; ATRIAL-FIBRILLATION; REPORTED OUTCOMES; ESC GUIDELINES; SHOCKS; SEX;
D O I
10.1186/s12872-021-02218-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Self-reported health status as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with primary prevention implantable cardioverter defibrillators (ICDs) has mainly been reported from randomized trials. However, these studies are often limited to short follow-up and are subject to selection bias. The aim of this study was to assess KCCQ-12 in patients with primary prevention ICD due to either ischemic or nonischemic heart failure. Methods This cross-sectional observational study included all patients in Region Gavleborg, Sweden, who because of primary prevention due to heart failure, had an ICD or underwent device replacement between 2007 and 2017. After validation using medical records patients were sent and returned the KCCQ-12 by regular mail. Results A total of 118 questionnaires were analyzed (response rate 71.1%). The mean age was 70.9 +/- 9.8 years, and a minority was female (n = 20, 16.9%). The mean overall summary score was 71.5 +/- 22.4, there was no significant difference between ischemic and nonischemic heart failure (69.5 +/- 23.1 vs. 74.4 +/- 21.3; p = 0.195). Atrial fibrillation at baseline was associated with lower score for the domains Symptom frequency (70.2 +/- 23.2 vs. 82.2 +/- 19.2; p = 0.006) and Social limitation (62.1 +/- 26.0 vs. 75.6 +/- 26.6; p = 0.006) as well as the overall summary score (63.9 +/- 21.3 vs. 74.8 +/- 22.2; p = 0.004). Conclusion In a real-world setting, primary prevention ICD patients with heart failure report an acceptable disease-specific health status at long-term follow-up. Ischemic and nonischemic etiology showed similar health status whereas atrial fibrillation was associated with worse outcome.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Health status measured by Kansas City Cardiomyopathy Questionnaire-12 in primary prevention implantable cardioverter defibrillator patients with heart failure
    Gustav Mattsson
    Marita Wallhagen
    Peter Magnusson
    BMC Cardiovascular Disorders, 21
  • [2] Validation of the Portuguese Version of the Kansas City Cardiomyopathy Questionnaire-12
    dos Reis, Mariane Cecilia
    Nascimento, Juliana Araujo
    de Andrade, Geisa Nascimento
    Costa, Ana Claudia de Souza
    Takada, Julio Yoshio
    Mansur, Antonio de Padua
    Bocchi, Edimar Alcides
    dos Santos, Gianni Mara Silva
    Spertus, John A.
    Nakagawa, Naomi Kondo
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (04)
  • [3] Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction
    Yang, Mingming
    Kondo, Toru
    Adamson, Carly
    Butt, Jawad H.
    Abraham, William T.
    Desai, Akshay S.
    Jering, Karola S.
    Kober, Lars
    Kosiborod, Mikhail N.
    Packer, Milton
    Rouleau, Jean L.
    Solomon, Scott D.
    Vaduganathan, Muthiah
    Zile, Michael R.
    Jhund, Pardeep S.
    McMurray, John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (09) : 1606 - 1618
  • [4] The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy
    Sauer, Andrew J.
    Sherrod, Charles F.
    Gosch, Kensey L.
    Arnold, Suzanne V.
    Reaney, Matthew
    Zhong, Yue
    Lam, Jenny
    Wyrwich, Kathleen W.
    Spertus, John A.
    CIRCULATION, 2023, 148
  • [5] The follow-up of patients with chronic heart failure and implantable cardioverter defibrillator in primary prevention
    Kerekanic, Michal
    Misikova, S.
    Komanova, E.
    Sedlak, J.
    Farkas, J.
    Stancak, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 38 - 39
  • [6] IS THERE A GENDER DISPARITY IN PATIENTS WITH SYSTOLIC HEART FAILURE RECEIVING AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FOR PRIMARY PREVENTION?
    Nahass, Meghan
    Hiltner, Emily
    Srivastava, Shreya
    Kassotis, John
    Sethi, Ankur
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 181 - 181
  • [7] The implantable cardioverter defibrillator in congestive heart failure patients in primary prevention: assessment of neuropsychological impact
    Garnero, S.
    Pomero, A.
    Vallauri, P.
    Leto, L.
    Testa, M.
    Feola, M.
    MINERVA CARDIOANGIOLOGICA, 2014, 62 (04): : 321 - 326
  • [8] Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure
    Green, CP
    Porter, CB
    Bresnahan, DR
    Spertus, JA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (05) : 1245 - 1255
  • [9] Primary prevention implantable cardioverter defibrillators for patients with heart failure
    Beggs, Simon A. S.
    Wright, Gary A.
    Gardner, Roy S.
    HEART, 2024, 110 (01) : 65 - 73
  • [10] Syncope in Primary Prevention Implantable Cardioverter Defibrillator Patients
    Goldenberg, Gustavo
    Bental, Tamir
    Kadmon, Udi
    Zabarsky, Ronit
    Kusnick, Jairo
    Barsheshet, Mon
    Golovchiner, Gregory
    Strasberg, Boris
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (06): : 318 - 321